Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1686385rdf:typepubmed:Citationlld:pubmed
pubmed-article:1686385lifeskim:mentionsumls-concept:C0012634lld:lifeskim
pubmed-article:1686385lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:1686385lifeskim:mentionsumls-concept:C0178601lld:lifeskim
pubmed-article:1686385lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:1686385pubmed:issue4lld:pubmed
pubmed-article:1686385pubmed:dateCreated1992-3-26lld:pubmed
pubmed-article:1686385pubmed:abstractTextArtificial dopamine agonists are widely employed for the treatment of idiopathic parkinsonism. Pleuropulmonary disease has previously been reported to occur with the use of bromocriptine and mesulergine. We report similar adverse effects induced by the newer agonists lisuride and cabergoline. All these agents are tetracyclic ergot derivatives. This suggests a causal link between ergot-derived dopamine agonists and pleuropulmonary disease.lld:pubmed
pubmed-article:1686385pubmed:languageenglld:pubmed
pubmed-article:1686385pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1686385pubmed:citationSubsetIMlld:pubmed
pubmed-article:1686385pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1686385pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1686385pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1686385pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1686385pubmed:statusMEDLINElld:pubmed
pubmed-article:1686385pubmed:monthOctlld:pubmed
pubmed-article:1686385pubmed:issn0364-5134lld:pubmed
pubmed-article:1686385pubmed:authorpubmed-author:CalneD BDBlld:pubmed
pubmed-article:1686385pubmed:authorpubmed-author:FleethamJ AJAlld:pubmed
pubmed-article:1686385pubmed:authorpubmed-author:BhattM HMHlld:pubmed
pubmed-article:1686385pubmed:authorpubmed-author:KeenanS PSPlld:pubmed
pubmed-article:1686385pubmed:issnTypePrintlld:pubmed
pubmed-article:1686385pubmed:volume30lld:pubmed
pubmed-article:1686385pubmed:ownerNLMlld:pubmed
pubmed-article:1686385pubmed:authorsCompleteYlld:pubmed
pubmed-article:1686385pubmed:pagination613-6lld:pubmed
pubmed-article:1686385pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1686385pubmed:meshHeadingpubmed-meshheading:1686385-...lld:pubmed
pubmed-article:1686385pubmed:meshHeadingpubmed-meshheading:1686385-...lld:pubmed
pubmed-article:1686385pubmed:meshHeadingpubmed-meshheading:1686385-...lld:pubmed
pubmed-article:1686385pubmed:meshHeadingpubmed-meshheading:1686385-...lld:pubmed
pubmed-article:1686385pubmed:meshHeadingpubmed-meshheading:1686385-...lld:pubmed
pubmed-article:1686385pubmed:meshHeadingpubmed-meshheading:1686385-...lld:pubmed
pubmed-article:1686385pubmed:meshHeadingpubmed-meshheading:1686385-...lld:pubmed
pubmed-article:1686385pubmed:meshHeadingpubmed-meshheading:1686385-...lld:pubmed
pubmed-article:1686385pubmed:meshHeadingpubmed-meshheading:1686385-...lld:pubmed
pubmed-article:1686385pubmed:meshHeadingpubmed-meshheading:1686385-...lld:pubmed
pubmed-article:1686385pubmed:meshHeadingpubmed-meshheading:1686385-...lld:pubmed
pubmed-article:1686385pubmed:year1991lld:pubmed
pubmed-article:1686385pubmed:articleTitlePleuropulmonary disease associated with dopamine agonist therapy.lld:pubmed
pubmed-article:1686385pubmed:affiliationBelzberg Laboratory of Clinical Neuroscience, Vancouver, Canada.lld:pubmed
pubmed-article:1686385pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1686385pubmed:publicationTypeCase Reportslld:pubmed
pubmed-article:1686385pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1686385lld:pubmed